<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Establishing the diagnosis of Cushing syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Establishing the diagnosis of Cushing syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Establishing the diagnosis of Cushing syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3744356171"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The possible presence of Cushing syndrome is suggested by certain symptoms and signs. Unfortunately, none of these are pathognomonic, and many are nonspecific (eg, obesity, hypertension, menstrual irregularity, and glucose intolerance). As a result, the diagnosis must be confirmed by biochemical tests. The diagnosis of Cushing syndrome involves three steps: suspecting it on the basis of the patient's symptoms and signs, documenting the presence of hypercortisolism, and determining its cause. The evaluation to determine if the patient has hypercortisolism (Cushing syndrome) will be reviewed here. The pathophysiology, causes, clinical manifestations, and approach to the differential diagnosis of established hypercortisolism is discussed separately. (See  <a class="medical medical_review" href="/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome"</a> and  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome"</a> and  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H108956977"><span class="h1">OVERVIEW OF DIAGNOSTIC APPROACH</span></p><p class="headingAnchor" id="H425721217"><span class="h2">Who should be tested?</span><span class="headingEndMark"> — </span>We suggest testing for hypercortisolism in patients in whom a diagnosis is most likely, including the following  (<a class="graphic graphic_table graphicRef111525" data-inline-graphics="111525" href="/d/graphic/111525.html" rel="external">table 1</a>) [<a href="#rid1">1-3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Unusual findings for their age (osteoporosis or hypertension in young adults).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple progressive features of Cushing syndrome, particularly those that are predictive of Cushing syndrome such as facial plethora, proximal myopathy, striae (&gt;1 cm wide and red/purple), and easy bruising.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained severe features (resistant hypertension, osteoporosis) at any age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adrenal incidentalomas.</p><p></p><p class="headingAnchor" id="H425721817"><span class="h2">Exclude exogenous glucocorticoids</span><span class="headingEndMark"> — </span>Before evaluation for possible Cushing syndrome, it is essential that a careful history has excluded exogenous glucocorticoid intake, as these patients should not be evaluated for Cushing syndrome:</p><p class="bulletIndent1"><span class="glyph">●</span>The most common cause of hypercortisolism is ingestion of prescribed glucocorticoid, usually for nonendocrine disease. However, Cushing syndrome can also be caused by other oral, injected, topical, and intranasal glucocorticoids [<a href="#rid4">4-6</a>] and by high doses of <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> or other progestins with some intrinsic glucocorticoid activity [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">Ritonavir</a> inhibits CYP3A4 metabolism of many glucocorticoids and can cause excessive exposure to some inhaled or injected steroids, leading to Cushing syndrome [<a href="#rid8">8,9</a>]. Cushing syndrome may also be caused by the use of glucocorticoid-containing creams or herbal preparations or overuse of glucocorticoids through any route of administration [<a href="#rid10">10,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All glucocorticoids (including potent inhaled and topical glucocorticoids, such as <a class="drug drug_general" data-topicid="9068" href="/d/drug information/9068.html" rel="external">beclomethasone</a> and <a class="drug drug_general" data-topicid="8458" href="/d/drug information/8458.html" rel="external">fluocinolone</a>, and especially inhaled <a class="drug drug_general" data-topicid="8951" href="/d/drug information/8951.html" rel="external">fluticasone</a>) inhibit corticotropin (ACTH) secretion if given in sufficient doses (see  <a class="medical medical_review" href="/d/html/540.html" rel="external">"Major side effects of inhaled glucocorticoids", section on 'Adrenal suppression'</a>). Thus, plasma ACTH and serum cortisol concentrations and urinary cortisol excretion (unless cortisol or cortisone is the steroid administered) may all be low [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">In contrast, urinary cortisol excretion may be falsely elevated with vulvovaginal application of <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surreptitious intake of glucocorticoids is known as <strong>factitious Cushing syndrome</strong>, a rare disorder that may be seen in individuals who are close to the health professions [<a href="#rid12">12,14</a>]. Factitious Cushing syndrome is responsible for less than 1 percent of patients with Cushing syndrome, but even a careful history may fail to detect this disorder and it may be difficult to exclude with laboratory tests [<a href="#rid14">14-16</a>].</p><p></p><p class="bulletIndent1">Important clues to the diagnosis are low or erratic values for urinary cortisol, suggesting ingestion of a synthetic glucocorticoid or intermittent ingestion of cortisol or cortisone [<a href="#rid14">14</a>], or excessive urinary cortisol values relative to serum cortisol concentrations, suggesting the addition of <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> to urine specimens [<a href="#rid16">16</a>]. The most valuable laboratory test is the detection of synthetic glucocorticoids in the urine by high-pressure liquid chromatography or by gas chromatography/mass spectometry (GCMS) [<a href="#rid12">12,14,15</a>]. This approach does not detect excessive ingestion of exogenous hydrocortisone, which is identical to endogenous cortisol.</p><p></p><p class="headingAnchor" id="H425722354"><span class="h2">Initial testing</span><span class="headingEndMark"> — </span>The initial diagnostic tests for hypercortisolism should be highly sensitive, even though the diagnosis may be excluded later by more specific tests [<a href="#rid17">17,18</a>]. The diagnosis of Cushing syndrome is established when at least two different first-line tests are unequivocally abnormal.</p><p>Once the diagnosis is established, additional evaluation is done to identify the cause of the hypercortisolism. (See  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a>.)</p><p>We agree with the diagnostic approach outlined by the evidence-based 2008 Endocrine Society clinical guidelines [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a low index of suspicion, we suggest initial testing with one of the following first-line tests: bedtime salivary cortisol (two measurements), 24-hour urinary free cortisol (UFC) excretion (two measurements), or the overnight 1 mg <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test (DST). For example, a woman with oligomenorrhea and hirsutism might be tested for Cushing syndrome; however, the pretest probability of the syndrome is low if there are no other associated signs or symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a high index of suspicion, such as those with features suggestive of Cushing syndrome, we do two or three first-line tests (with at least two measurements for UFC or salivary cortisol).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To optimize sensitivity, we suggest using the upper limit of the reference range for UFC and salivary cortisol and a serum cortisol concentration &lt;1.8 mcg/dL (50 nmol/L) after <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> as the criteria for a normal response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If UFC is chosen as the initial screening test, the result should be unequivocally increased (threefold above the upper limit of normal for the assay), or the diagnosis of Cushing syndrome remains uncertain and other tests should be performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some centers use the longer low-dose DST (2 mg/day for 48 hours) as an initial test [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>UFC and bedtime salivary cortisol measurements are each obtained at least twice because the hypercortisolism in Cushing syndrome may be variable. Two measurements must be abnormal for the test to be considered abnormal; for patients with mild or fluctuating disease, this may require collecting a number of salivary cortisols or UFCs over weeks.</p><p></p><p class="headingAnchor" id="H853123611"><span class="h3">Normal results</span><span class="headingEndMark"> — </span>If initial testing is normal in an individual with a low index of suspicion for Cushing syndrome, it is unlikely that the patient has Cushing syndrome unless it is extremely mild or cyclic. We do not suggest additional evaluation unless symptoms progress or cyclic Cushing syndrome is suspected. In this case, we suggest referral to an endocrinologist for repeat testing and further evaluation.</p><p>On the other hand, if initial testing is normal in someone with a high index of suspicion for Cushing syndrome (clinical features suggestive of Cushing syndrome), we suggest referral to an endocrinologist for additional evaluation to confirm or exclude the diagnosis of Cushing syndrome.</p><p class="headingAnchor" id="H853123618"><span class="h3">Any abnormal result</span><span class="headingEndMark"> — </span>In patients with at least one abnormal test result (which could represent true Cushing syndrome or a false-positive result), we suggest additional evaluation. This includes excluding physiologic hypercortisolism and referral to an endocrinologist. Additional evaluation may include repeating the initial test or other first-line tests.</p><p class="headingAnchor" id="H853123632"><span class="h4">Exclude physiologic hypercortisolism</span><span class="headingEndMark"> — </span>Hypercortisolism can occur in several disorders other than Cushing syndrome [<a href="#rid2">2</a>]. When such patients present with clinical features consistent with Cushing syndrome, they may also be referred to as having physiologic hypercortisolism or pseudo-Cushing syndrome. Clinically, patients with these physiologic forms of hypercortisolism seldom have the cutaneous (ie, easy bruising, thinning, and friability) or muscle (ie, proximal muscle atrophy and weakness) signs of Cushing syndrome [<a href="#rid17">17</a>]. These conditions/disorders should be excluded when evaluating patients for Cushing syndrome.</p><p>Examples of conditions associated with physiologic hypercortisolism that may have some clinical features of Cushing syndrome include:</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with severe obesity, especially those with visceral obesity or polycystic ovary syndrome (PCOS)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with psychological stress, especially patients with a severe major depressive disorder and melancholic symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Poorly controlled diabetes mellitus</p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, chronic alcoholism, especially during withdrawal</p><p class="bulletIndent1"><span class="glyph">●</span>Physical stress (illness, hospitalization/surgery, pain)</p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive sleep apnea</p><p></p><p>Examples of conditions associated with physiologic hypercortisolism that are <strong>unlikely</strong> to have clinical features of Cushing syndrome include:</p><p class="bulletIndent1"><span class="glyph">●</span>Malnutrition, anorexia nervosa</p><p class="bulletIndent1"><span class="glyph">●</span>Intense chronic exercise</p><p class="bulletIndent1"><span class="glyph">●</span>Hypothalamic amenorrhea</p><p class="bulletIndent1"><span class="glyph">●</span>High corticosteroid-binding globulin (CBG) (increased serum cortisol but not UFC)</p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoid resistance</p><p></p><p>We suggest against routine testing for Cushing syndrome in these patients unless they develop features predictive of Cushing syndrome such as wide purplish stria, proximal myopathy, or easy bruising.</p><p>The distinction between physiologic hypercortisolism and Cushing syndrome is not always simple because patients with Cushing syndrome can have serious infections, frequently have depression (although it is often an atypical, agitated depression) [<a href="#rid19">19,20</a>], and presumably have a prevalence of chronic alcoholism similar to that of the general population.</p><p>The psychiatric literature suggests that as many as 80 percent of patients with major depressive disorders have increased cortisol secretion [<a href="#rid21">21-23</a>]. However, cortisol hypersecretion, when present, is usually mild. Furthermore, even patients with severe depression and substantial cortisol hypersecretion rarely develop clinical Cushing syndrome. However, some patients with depression may be difficult to distinguish clinically or biochemically from those with Cushing disease. Their abnormal cortisol secretion presumably results from hypothalamic-pituitary-adrenal (HPA) axis hyperactivity [<a href="#rid22">22</a>], and disappears after remission of depression [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/118669.html" rel="external">"Unipolar depression: Neurobiology", section on 'Hypothalamic-pituitary-adrenal axis'</a>.)</p><p>Approximately 70 patients with chronic alcoholism and clinical or biochemical manifestations of Cushing syndrome have been reported [<a href="#rid25">25,26</a>]. Most had liver dysfunction, although the hormonal changes did not correlate closely with the degree of abnormality in liver function. In addition to liver dysfunction, these patients probably have transiently increased secretion of corticotropin-releasing hormone (CRH) or impaired hypothalamic or pituitary responsiveness to cortisol. However, their peripheral and petrosal sinus plasma CRH concentrations are normal, although these tests are not clinically indicated [<a href="#rid27">27</a>]. The hormonal abnormalities disappear rapidly during abstinence from alcohol.</p><p>Females with hypothalamic amenorrhea due to stress or weight loss also may have elevated UFC [<a href="#rid28">28</a>], and male obligate exercisers have increased evening cortisol and ACTH levels [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/7393.html" rel="external">"Functional hypothalamic amenorrhea: Pathophysiology and clinical manifestations"</a>.)</p><p>UFC and cortisol values normalize in patients with anorexia nervosa who gain weight and normalize body mass index (BMI) [<a href="#rid30">30</a>] (see  <a class="medical medical_review" href="/d/html/86685.html" rel="external">"Anorexia nervosa: Endocrine complications and their management", section on 'Adrenal'</a>). This suggests that treatment of other physiologic causes of hypercortisolism may result in normalization of UFC and assist in the discrimination between these physiologic states and Cushing syndrome.</p><p class="headingAnchor" id="H863206684"><span class="h4">CRH after dexamethasone test</span><span class="headingEndMark"> — </span>The corticotropin-releasing hormone (CRH; <a class="drug drug_general" data-topicid="8866" href="/d/drug information/8866.html" rel="external">corticorelin</a>) after <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> test exploits the greater sensitivity of ACTH secretion to dexamethasone suppression in patients with depression or other causes of physiologic hypercortisolism [<a href="#rid31">31,32</a>] and their blunted serum cortisol response to exogenous CRH as compared with healthy people or patients with Cushing disease [<a href="#rid23">23,32</a>]. While this test has diagnostic accuracy similar to other screening tests [<a href="#rid33">33</a>], CRH is no longer available worldwide.</p><p class="headingAnchor" id="H853123625"><span class="h4">Refer to endocrinologist for additional testing</span><span class="headingEndMark"> — </span>As noted, in patients with at least one abnormal test result, we suggest referral to an endocrinologist for additional evaluation. Additional evaluation may include repeating the abnormal study or other first-line tests.</p><p class="headingAnchor" id="H853123932"><span class="h5">Normal (Cushing syndrome unlikely)</span><span class="headingEndMark"> — </span>We suggest no further testing for Cushing syndrome in patients with negative results on two different tests (unless cyclical disease is suspected, which is rare).</p><p class="headingAnchor" id="H853123939"><span class="h5">Abnormal (Cushing syndrome confirmed)</span><span class="headingEndMark"> — </span>The diagnosis of Cushing syndrome is established when at least two different first-line tests are unequivocally abnormal [<a href="#rid1">1</a>], and physiologic hypercortisolism has been excluded. Once the diagnosis is established, additional evaluation is done to identify the cause of the hypercortisolism. (See  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a>.)</p><p>For the occasional patient with a high pretest probability of Cushing syndrome but negative or discordant results on initial and repeat testing, we suggest follow-up with additional testing.</p><p class="headingAnchor" id="H830418316"><span class="h2">Delays in diagnosis</span><span class="headingEndMark"> — </span>Early diagnosis is important to avoid the complications and excess mortality associated with Cushing syndrome. However, for most patients, it takes years to be diagnosed [<a href="#rid34">34</a>]. In some patients, this may be due to clinical features that are both nonspecific and common in individuals without hypercortisolism (hypertension, obesity, and glucose intolerance). (See  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome"</a>.)</p><p>In a meta-analysis of 44 studies (including 5367 patients), the mean time to diagnosis was 38 months (95% CI 33-43) for patients with pituitary Cushing syndrome and 30 months (95% CI 24-36) for adrenal Cushing syndrome. The duration was shorter for those with ectopic Cushing syndrome, likely due to the severity of their hypercortisolism (14 months [95% CI 11-17]) [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H6"><span class="h1">AVAILABLE TESTS</span><span class="headingEndMark"> — </span>None of the initial tests have ideal sensitivity or specificity. For example, in one study of 369 patients with overweight or obesity, and two additional features of Cushing syndrome, the specificity of diagnostic tests ranged from 84 to 96 percent [<a href="#rid35">35</a>]. In a meta-analysis of 139 studies in 14,140 participants, all initial screening tests had comparable sensitivity and specificity [<a href="#rid33">33</a>]. As no one test is superior to others, the choice of test should be individualized to minimize false-positive results.</p><p>For example, a bedtime salivary cortisol test is likely to be abnormal in a shift worker, and a <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test (DST) response may be abnormal in a woman taking oral estrogen, because of increased corticosteroid-binding globulin (CBG; and hence total cortisol). These tests would not be ideal, and other tests would be chosen based on the individual's history and lifestyle.</p><p class="headingAnchor" id="H7"><span class="h2">24-hour urinary cortisol excretion</span><span class="headingEndMark"> — </span>Urinary cortisol excretion over 24 hours provides a direct and reliable practical index of cortisol secretion [<a href="#rid36">36,37</a>]. Corticotropin (ACTH) and cortisol are secreted in discrete bursts, not only in normal subjects but also in most patients with Cushing disease [<a href="#rid38">38-40</a>]; in addition, cortisol is secreted episodically by some adrenal tumors  (<a class="graphic graphic_figure graphicRef60086" href="/d/graphic/60086.html" rel="external">figure 1</a>) [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/170.html" rel="external">"Measurement of urinary excretion of endogenous and exogenous glucocorticoids"</a>.)</p><p>Urinary cortisol excretion over 24 hours is an integrated measure of the serum free cortisol concentration (ie, cortisol that is not bound to CBG [transcortin] or other serum proteins). The two most important factors in obtaining a valid result are collection of a complete 24-hour specimen and a reliable reference laboratory. The former can usually be obtained by carefully explaining to the patient how to collect the specimen and by measuring urinary creatinine excretion (see  <a class="medical medical_patient" href="/d/html/2181.html" rel="external">"Patient education: Collection of a 24-hour urine specimen (Beyond the Basics)"</a>). Urinary cortisol assays are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/170.html" rel="external">"Measurement of urinary excretion of endogenous and exogenous glucocorticoids", section on 'Types of assays'</a>.)</p><p>The best evidence for the utility of urinary free cortisol (UFC) as a screening test comes from a systematic review and meta-analysis of studies of diagnostic tests for Cushing syndrome performed in conjunction with the 2008 Endocrine Society guidelines [<a href="#rid41">41</a>]. Tests with a high likelihood ratio for a positive (abnormal) result indicate tests that help rule in Cushing syndrome, while those with a very low likelihood ratio for a negative (normal) result indicate tests that help rule it out. Salivary cortisol, UFC, and the overnight DST had similar accuracy. For urinary cortisol, 14 studies were included of 646 patients with Cushing syndrome and 5226 patients who did not have Cushing syndrome. The likelihood ratio of 10.6 (95% CI 5.5-20.5) for an abnormal result and a likelihood ratio for Cushing syndrome of 0.16 (95% CI 0.08-0.33) for a normal result. However, other studies suggest that in cases of mild Cushing syndrome, UFC has less diagnostic sensitivity than salivary cortisol [<a href="#rid42">42,43</a>]. Although liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods are more analytically specific than immunoassays, their use for measuring UFC has been questioned, as they give a lower (and potentially falsely negative) result [<a href="#rid44">44</a>].</p><p>Some experts argue that UFC determinations are unnecessary because bedtime serum or salivary cortisol values have similar diagnostic utility and are more convenient (see <a class="local">'Bedtime salivary cortisol'</a> below). If it is not convenient to collect urine as a second test, then the DST should be used in combination with a bedtime cortisol test.</p><p class="headingAnchor" id="H425723401"><span class="h3">Interpretation and limitations</span><span class="headingEndMark"> — </span>The patient can be assumed to have Cushing syndrome if basal urinary cortisol excretion is more than three times the upper limit of normal (which may vary somewhat in different assays) and one other test is abnormal. The patient should then be evaluated for the cause of the hypercortisolism. (See  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subclinical hypercortisolism</strong> – UFC is of limited utility in patients with subclinical hypercortisolism (eg, patients with mild Cushing syndrome caused by an adrenal incidentaloma). These patients may have normal urine cortisol values but an elevated bedtime salivary cortisol concentration [<a href="#rid1">1</a>]. The overnight DST is suggested for patients with adrenal incidentalomas. (See  <a class="medical medical_review" href="/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'Subclinical Cushing syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>False-positive results</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Physiologic hypercortisolism</strong> – Patients with equivocally raised urine cortisol values (above normal but less than three times the upper reference value) may have physiologic hypercortisolism (pseudo-Cushing syndrome). For example, up to 40 percent of patients with severe depression or polycystic ovary syndrome (PCOS) have slightly high 24-hour urinary cortisol excretion [<a href="#rid14">14,45</a>]. In this setting, patients should either be reevaluated after several weeks <strong>or</strong> undergo one or more of the other first-line tests, depending upon the level of clinical suspicion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High fluid intake</strong> – People who drink very large volumes of liquid also excrete more cortisol (64 percent more cortisol excreted with an intake of 5 liters per day), while excretion of creatinine and 17-hydroxycorticosteroids remains unaltered [<a href="#rid46">46</a>]. Therefore, modest increases of urinary cortisol excretion in patients with urine volumes of more than 3 liters should be interpreted with caution.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>False-negative results</strong> – If urinary cortisol excretion is indeterminate (above the upper limit of the reference range but less than threefold above the upper limit), and the bedtime serum or salivary cortisol concentrations are normal, the patient does not have Cushing syndrome unless it is cyclic or mild [<a href="#rid42">42,47</a>].</p><p></p><p class="bulletIndent1">A few studies report that some patients with Cushing disease may have normal UFC (measured by tandem mass spectrometry) but are more likely to have abnormal bedtime salivary cortisol [<a href="#rid42">42,48</a>]. In a study of 426 patients with Cushing syndrome, for example, 47 percent of 288 patients with Cushing disease, 31 percent of 80 patients with adrenal adenoma, 21 percent of 25 patients with ectopic ACTH or corticotropin-releasing hormone (CRH) secretion, and 5 percent of 24 patients with adrenal carcinoma had at least one 24-hour urinary cortisol value in this equivocal range [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">These examples illustrate the need for complementary tests, careful consideration of the tests that are chosen, and correlation of the test results.</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Bedtime salivary cortisol</span><span class="headingEndMark"> — </span>A bedtime salivary cortisol concentration can be used to establish the diagnosis of Cushing syndrome [<a href="#rid50">50-57</a>]. Measurement of salivary cortisol in the late evening before bedtime is based upon the fact that the normal evening nadir in serum cortisol is preserved in patients with physiologic hypercortisolism but not in those with Cushing syndrome (see  <a class="medical medical_review" href="/d/html/161.html" rel="external">"Measurement of cortisol in serum and saliva"</a>). Because cortisol levels appear to be entrained to the initiation of sleep, bedtime salivary cortisol measurement is not a good test for patients with erratic sleep schedules or shift work.</p><p>Saliva collection has many advantages: it is noninvasive and can be easily performed by the patient at home, and cortisol is stable in saliva even at room temperature for several days. This test is especially useful for patients suspected of having cyclical or intermittent Cushing syndrome, who can collect many samples over an extended period of time and return the accumulated samples to the laboratory at one time. As with other cortisol assays, it is useful to evaluate at least three samples from different days. Bedtime saliva collection can be performed during 24-hour urine collection for UFC to allow corroboration of test results. (See <a class="local">'24-hour urinary cortisol excretion'</a> above.)</p><p>The criteria used to interpret salivary cortisol results differ among studies because of assay differences. As a result, published reference ranges are not appropriate for all commercial assays  (<a class="graphic graphic_table graphicRef57112" href="/d/graphic/57112.html" rel="external">table 2</a>) [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/161.html" rel="external">"Measurement of cortisol in serum and saliva"</a>.)</p><p>In addition, a study of older men (mean age 61 years), some with comorbidities of diabetes and/or hypertension, showed poor test specificity. Twenty percent of the participants had false-positive results (eg, a bedtime salivary cortisol value above the upper limit of normal [1.6 ng/mL, 4.3 nmol/L] when measured by enzyme immunoassay) [<a href="#rid59">59</a>]. None had Cushing syndrome.</p><p>In the meta-analysis for the Endocrine Society guidelines described above, bedtime salivary cortisol was an accurate diagnostic test based upon pooled analysis of four studies in 136 patients with Cushing syndrome [<a href="#rid41">41</a>]. The likelihood ratio for an abnormal (positive) result was 8.8 (95% CI 3.5-21.8), and for a normal (negative) result, the likelihood ratio was 0.07 (95% CI 0.00-1.20). The larger meta-analysis that included 1868 patients with Cushing syndrome and 5049 without Cushing syndrome found similar positive (14.6, 95% CI 10.3-20.7) and negative (0.045, 95% CI 0.030-0.066) likelihood ratios [<a href="#rid33">33</a>]. </p><p>Thus, while a bedtime salivary cortisol measurement is a useful test for the diagnosis of Cushing syndrome, appropriate assay-specific and perhaps age-specific normative values must be used for its interpretation.</p><p>In some situations, other second-line tests may be used. These tests may be chosen because of site-specific constraints, lack of access to salivary cortisol assays, or preferences based on experience.</p><p class="headingAnchor" id="H10"><span class="h2">Bedtime serum cortisol</span><span class="headingEndMark"> — </span>As noted for bedtime salivary cortisol, measurement of serum cortisol in the late evening, usually at midnight, is also based upon the fact that the normal nadir in serum cortisol after sleep onset is preserved in patients with physiologic hypercortisolism but not in those with Cushing syndrome. This test is less convenient than the bedtime salivary cortisol and is therefore not used routinely in clinical practice. However, it is sometimes used at specialized centers.</p><p>A bedtime serum cortisol &gt;7.5 mcg/dL (207 nmol/L) is used to identify Cushing syndrome. This is based upon a study of 198 patients with Cushing disease, 27 patients with ectopic ACTH syndrome, 15 patients with primary adrenal Cushing syndrome, and 23 patients with pseudo-Cushing syndrome. A single bedtime serum cortisol concentration &gt;7.5 mcg/dL (207 nmol/L) correctly identified 225 of 234 patients with Cushing syndrome; normal values were seen in all 23 patients with pseudo-Cushing syndrome (96 percent sensitivity, 100 percent specificity) [<a href="#rid60">60</a>].</p><p>This test has usually been performed in the hospital, and one group obtains the blood after the patient appears to be asleep [<a href="#rid61">61</a>]. However, sleeping versus awake results have not been evaluated systematically, and our experience is that the test can reliably be performed on an ambulatory basis. This can be done by inserting a heparin-lock earlier in the day to avoid stress-induced cortisol release caused by the anticipation of or pain caused by venipuncture and asking the patient to return between 11 PM and midnight for blood drawing. We try to obtain samples on at least two evenings. (See  <a class="medical medical_review" href="/d/html/161.html" rel="external">"Measurement of cortisol in serum and saliva"</a>.)</p><p class="headingAnchor" id="H108956464"><span class="h2">Low-dose dexamethasone suppression tests</span><span class="headingEndMark"> — </span>The low-dose DSTs are standard <strong>screening</strong> tests to differentiate patients with Cushing syndrome of any cause from patients who do not have Cushing syndrome. The high-dose DSTs are <strong>not</strong> used to make the diagnosis of Cushing syndrome. They are used after the diagnosis of Cushing syndrome is made to distinguish patients with Cushing disease (Cushing syndrome caused by pituitary hypersecretion of ACTH) from patients with ectopic ACTH syndrome (Cushing syndrome caused by nonpituitary ACTH-secreting tumors). (See  <a class="medical medical_review" href="/d/html/160.html" rel="external">"Dexamethasone suppression tests"</a> and  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a>.)</p><p>There are two forms of low-dose DST: the 1 mg "overnight" and the two-day 2 mg test [<a href="#rid19">19</a>]. These tests are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/160.html" rel="external">"Dexamethasone suppression tests"</a>.)</p><p>The DSTs are <strong>not</strong> a good choice for patients in whom CBG levels may be abnormal or in those taking medications that may alter the metabolism of the drug [<a href="#rid62">62</a>]. Estrogen and estrogen-containing drugs, such as oral contraceptives, raise CBG and may result in a false-positive DST. Oral contraceptives should be stopped for six weeks before performing a DST, or an alternate test should be used. For the same reason, DSTs are also not a reliable test in pregnancy. (See <a class="local">'Pregnancy'</a> below and  <a class="medical medical_review" href="/d/html/139.html" rel="external">"Diagnosis and management of Cushing syndrome during pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overnight 1 mg test</strong> – The overnight test consists of administration of 1 mg of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> at 11 PM to 12 AM (midnight) and measurement of serum cortisol at 8 AM the next morning. (See  <a class="medical medical_review" href="/d/html/161.html" rel="external">"Measurement of cortisol in serum and saliva"</a>.)</p><p></p><p class="bulletIndent1">The 2008 Endocrine Society guidelines suggest a diagnostic cortisol criterion of 1.8 mcg/dL (50 nmol/L), recognizing that this choice will optimize sensitivity but decrease specificity. Despite use of this stringent criterion for sensitivity, in one study, 8 percent (6 of 80) patients with Cushing disease showed suppression to less than 2 mcg/dL (55 nmol/L) [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1">The low-dose DST should <strong>not</strong> be used as the sole criterion for the diagnosis of Cushing syndrome. At least one additional test should be done to establish or exclude the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Standard two-day 2 mg test</strong> – The two-day 2 mg test, which is done commonly in some countries but not others, consists of administering 0.5 mg of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> every six hours for eight doses, and measurement of serum (not urinary) cortisol either two or six hours after the last dose. The same criteria for normal suppression (&lt;1.8 mcg/dL [&lt;50 nmol/L]) used for the 1 mg DST are used for the two-day 2 mg DST. The two-day 2 mg DST is described in greater detail separately. (See  <a class="medical medical_review" href="/d/html/160.html" rel="external">"Dexamethasone suppression tests"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic accuracy</strong> – In the meta-analyses described above, the 1 mg DST and the two-day 2 mg DST were both accurate diagnostic tests [<a href="#rid33">33,41</a>] (see <a class="local">'24-hour urinary cortisol excretion'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the 1 mg DST, in 14 studies including 249 patients with Cushing syndrome out of 5305 undergoing testing (using various diagnostic criteria), there was a likelihood ratio of 16.4 (95% CI 9.3-28.8) for an abnormal (positive) result and 0.06 (95% CI 0.03-0.14) for a normal (negative) result [<a href="#rid41">41</a>]. In the larger analysis that included 1531 patients with Cushing syndrome out of 4798 undergoing testing, the likelihood ratios were similar, with a positive likelihood ratio of 10.5 (95% CI 7.2-15.3) and a negative likelihood ratio of 0.016 (95% CI 0.007-0.035) [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the two-day 2 mg test, the first analysis identified eight studies, including 136 patients with Cushing syndrome out of 323 who were tested. It found a likelihood ratio of 7.3 (95% CI 3.6-15.2) for an abnormal result and 0.18 (95% CI 0.06-0.52) for a normal result [<a href="#rid41">41</a>]. The larger analysis included 569 patients with Cushing syndrome out of 1095 undergoing testing. The findings were similar, with a positive likelihood ratio of 13.2 (95% CI 6.47-27.1) and a negative likelihood ratio of 0.051 (95% CI 0.027-0.095) [<a href="#rid33">33</a>].</p><p></p><p>Serum collected at the time of cortisol measurement should be retained for measurement of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (available in commercial laboratories), to clarify otherwise confusing results caused by noncompliance and individual variability in, and drug effects on, dexamethasone metabolism [<a href="#rid64">64,65</a>]. (See  <a class="medical medical_review" href="/d/html/160.html" rel="external">"Dexamethasone suppression tests"</a>.)</p><p class="headingAnchor" id="H108956846"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H108956853"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>We suggest a 24-hour urinary free cortisol (UFC) test or bedtime salivary cortisol test in pregnant people with suspected Cushing syndrome rather than the low-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test (DST) [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/139.html" rel="external">"Diagnosis and management of Cushing syndrome during pregnancy", section on 'Diagnosis during pregnancy'</a>.)</p><p class="headingAnchor" id="H108956033"><span class="h2">Adrenal incidentaloma</span><span class="headingEndMark"> — </span>Subtle dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, manifest by abnormal response to DST, is the most frequent hormonal abnormality detected. Therefore, we suggest the 1 mg DST as the first-line test to screen for hypercortisolism in these patients (see  <a class="medical medical_review" href="/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma"</a> and <a class="local">'Interpretation and limitations'</a> above). Some adrenal incidentalomas secrete sufficient cortisol to suppress corticotropin (ACTH), at least partially. Although these patients lack many of the usual stigmata of overt Cushing syndrome, they may have one or more of the effects of endogenous cortisol over-secretion (eg, obesity, hypertension, glucose intolerance or diabetes, dyslipidemia, osteoporosis).</p><p>Depending on the importance of cortisol secretion by primary adrenal tumors, the spectrum of biochemical abnormalities will vary. Milder cases will present normal 24-hour UFC levels with slightly elevated bedtime salivary cortisol, incompletely suppressed morning serum cortisol following 1 mg DST, and partially suppressed plasma ACTH levels. In more severe cases, UFC, bedtime cortisol, and serum cortisol following 1 mg DST will be clearly elevated and plasma ACTH may be undetectable [<a href="#rid67">67</a>]. Testing with 1 mg DST is most likely to be abnormal in this population and should be undertaken only if there are metabolic and other features compatible with Cushing syndrome, as patients without any clinical features would not undergo treatment. This topic is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma"</a>.)</p><p class="headingAnchor" id="H108956899"><span class="h2">Cyclic Cushing syndrome</span><span class="headingEndMark"> — </span>Some patients have cyclic Cushing syndrome, which is characterized by episodes of cortisol excess alternating with periods of normal cortisol secretion. The episodes of hypercortisolism can occur regularly or irregularly, with intercyclic phases ranging from days to months [<a href="#rid47">47</a>]. For patients with suspected cyclic Cushing syndrome, we suggest UFC or bedtime salivary cortisol over the DST. If initial testing is normal but clinical suspicion is high, we suggest follow-up with repeat testing. True cyclic Cushing syndrome is relatively rare, but variability in UFC excretion is common in all etiologies of Cushing syndrome [<a href="#rid68">68,69</a>].</p><p class="headingAnchor" id="H108956906"><span class="h2">Other</span><span class="headingEndMark"> — </span>For patients with chronic kidney disease, we suggest the 1 mg overnight DST instead of UFC. For those with epilepsy, UFC or bedtime cortisols rather than the DST are suggested because antiseizure medications increase <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> clearance.</p><p>The overnight DST is unreliable (false-positive results) in females taking oral contraceptives because of the increase in corticosteroid-binding globulin (CBG). Ideally, oral contraceptives or other forms of estrogen should be held for six weeks before initiating testing.</p><p class="headingAnchor" id="H910732696"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112709.html" rel="external">"Society guideline links: Diagnosis and treatment of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H438736"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15600.html" rel="external">"Patient education: Cushing syndrome (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2173.html" rel="external">"Patient education: Cushing syndrome (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2177.html" rel="external">"Patient education: Cushing syndrome treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Who should be tested?</strong> –<strong> </strong>We suggest testing for hypercortisolism in patients in whom a diagnosis is most likely, including those with (see <a class="local">'Who should be tested?'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unusual findings for their age (osteoporosis or hypertension in young adults).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple progressive features of Cushing syndrome, particularly those that are predictive of Cushing syndrome such as facial plethora, proximal myopathy, striae (&gt;1 cm wide and red/purple), and easy bruising. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unexplained severe features (resistant hypertension, osteoporosis) at any age.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adrenal incidentalomas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exclude exogenous glucocorticoid use</strong> –<strong> </strong>Before evaluation for possible Cushing syndrome, it is essential that a careful history has excluded exogenous glucocorticoid intake as these patients should not be evaluated for Cushing syndrome. (See <a class="local">'Exclude exogenous glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial testing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a low index of suspicion, we suggest initial testing with <strong>one</strong> of the following first-line tests: bedtime salivary cortisol (two measurements), 24-hour urinary free cortisol (UFC) excretion (two measurements), or the overnight 1 mg <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test (DST). (See <a class="local">'Initial testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a high index of suspicion, we suggest initial testing with <strong>two or three </strong>of the first-line tests: bedtime salivary cortisol (two measurements), 24-hour urinary free cortisol (UFC) excretion (two measurements), or the overnight 1 mg <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression text (DST). (See <a class="local">'Initial testing'</a> above.)</p><p></p><p class="bulletIndent1">If UFC is chosen as the initial screening test, the result should be unequivocally increased (threefold above the upper limit of normal for the assay), or the diagnosis of Cushing syndrome is uncertain and other tests should be performed. (See <a class="local">'Initial testing'</a> above.)</p><p></p><p class="bulletIndent1">We suggest using the upper limit of the reference range for UFC and salivary cortisol and a serum cortisol concentration &lt;1.8 mcg/dL (50 nmol/L) after <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> as the cutoffs for a normal response. (See <a class="local">'Initial testing'</a> above.)</p><p></p><p class="bulletIndent1">Our choice of initial tests in special situations (pregnancy, adrenal incidentalomas, cyclic Cushing syndrome) are reviewed above. (See <a class="local">'Special populations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation</strong> –<strong> </strong>In patients with at least one abnormal test result (which could represent true Cushing syndrome or a false-positive result), we suggest additional evaluation. This includes excluding physiologic hypercortisolism and referral to an endocrinologist. Additional evaluation may include repeating the initial test or other first-line tests. (See <a class="local">'Any abnormal result'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Establish the diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis of Cushing syndrome is established when at least two different first-line tests are unequivocally abnormal and cannot be explained by other conditions that cause physiologic hypercortisolism. The patient should undergo additional evaluation if only one test is abnormal or only slightly abnormal. (See <a class="local">'Abnormal (Cushing syndrome confirmed)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If test results are normal, the patient does not have Cushing syndrome unless it is extremely mild or cyclic. We do not suggest additional evaluation unless symptoms progress or cyclic Cushing syndrome is suspected. (See <a class="local">'Normal (Cushing syndrome unlikely)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Once the diagnosis is established, additional evaluation is done to identify the cause of the hypercortisolism. (See  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H27157247"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526.</a></li><li><a class="nounderline abstract_t">Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing's syndrome. Lancet 2015; 386:913.</a></li><li><a class="nounderline abstract_t">Braun LT, Vogel F, Zopp S, et al.. Whom should we screen for Cushing Syndrome? The Endocrine Society Clinical Practice Guideline Recommendations 2008 Revisited. Journal of Clinical Endocrinology and Metabolism 2022; 107:e3723.</a></li><li><a class="nounderline abstract_t">Weber SL. Cushing'S syndrome attributable to topical use of lotrisone. Endocr Pract 1997; 3:140.</a></li><li><a class="nounderline abstract_t">Nutting CM, Page SR. Iatrogenic Cushing's syndrome due to nasal betamethasone: a problem not to be sniffed at! Postgrad Med J 1995; 71:231.</a></li><li><a class="nounderline abstract_t">Hughes JM, Hichens M, Booze GW, Thorner MO. Cushing's syndrome from the therapeutic use of intramuscular dexamethasone acetate. Arch Intern Med 1986; 146:1848.</a></li><li><a class="nounderline abstract_t">Mann M, Koller E, Murgo A, et al. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997; 157:1651.</a></li><li><a class="nounderline abstract_t">Samaras K, Pett S, Gowers A, et al. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005; 90:4394.</a></li><li><a class="nounderline abstract_t">Schwarze-Zander C, Klingmüller D, Klümper J, et al. Triamcinolone and ritonavir leading to drug-induced Cushing syndrome and adrenal suppression: description of a new case and review of the literature. Infection 2013; 41:1183.</a></li><li><a class="nounderline abstract_t">Olumide YM, Akinkugbe AO, Altraide D, et al. Complications of chronic use of skin lightening cosmetics. Int J Dermatol 2008; 47:344.</a></li><li><a class="nounderline abstract_t">Oldenburg-Ligtenberg PC, van der Westerlaken MM. A woman with Cushing's syndrome after use of an Indonesian herb: a case report. Neth J Med 2007; 65:150.</a></li><li><a class="nounderline abstract_t">Quddusi S, Browne P, Toivola B, Hirsch IB. Cushing syndrome due to surreptitious glucocorticoid administration. Arch Intern Med 1998; 158:294.</a></li><li><a class="nounderline abstract_t">Kelly CJ, Ogilvie A, Evans JR, et al. Raised cortisol excretion rate in urine and contamination by topical steroids. BMJ 2001; 322:594.</a></li><li><a class="nounderline abstract_t">Cizza G, Nieman LK, Doppman JL, et al. Factitious Cushing syndrome. J Clin Endocrinol Metab 1996; 81:3573.</a></li><li><a class="nounderline abstract_t">Lin CL, Wu TJ, Machacek DA, et al. Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:151.</a></li><li><a class="nounderline abstract_t">Workman RJ, Nicholson WE, McCammon DK. Factitious hypercortisoluria. J Clin Endocrinol Metab 1995; 80:3050.</a></li><li><a class="nounderline abstract_t">Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88:5593.</a></li><li><a class="nounderline abstract_t">Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19:647.</a></li><li><a class="nounderline abstract_t">LIDDLE GW. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1960; 20:1539.</a></li><li><a class="nounderline abstract_t">Loosen PT, Chambliss B, DeBold CR, et al. Psychiatric phenomenology in Cushing's disease. Pharmacopsychiatry 1992; 25:192.</a></li><li><a class="nounderline abstract_t">Pfohl B, Sherman B, Schlechte J, Winokur G. Differences in plasma ACTH and cortisol between depressed patients and normal controls. Biol Psychiatry 1985; 20:1055.</a></li><li><a class="nounderline abstract_t">Pfohl B, Sherman B, Schlechte J, Stone R. Pituitary-adrenal axis rhythm disturbances in psychiatric depression. Arch Gen Psychiatry 1985; 42:897.</a></li><li><a class="nounderline abstract_t">Gold PW, Loriaux DL, Roy A, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med 1986; 314:1329.</a></li><li><a class="nounderline abstract_t">Amsterdam JD, Maislin G, Winokur A, et al. The oCRH stimulation test before and after clinical recovery from depression. J Affect Disord 1988; 14:213.</a></li><li><a class="nounderline abstract_t">Groote Veldman R, Meinders AE. On the mechanism of alcohol-induced pseudo-Cushing's syndrome. Endocr Rev 1996; 17:262.</a></li><li><a class="nounderline abstract_t">Besemer F, Pereira AM, Smit JW. Alcohol-induced Cushing syndrome. Hypercortisolism caused by alcohol abuse. Neth J Med 2011; 69:318.</a></li><li><a class="nounderline abstract_t">Yanovski JA, Nieman LK, Doppman JL, et al. Plasma levels of corticotropin-releasing hormone in the inferior petrosal sinuses of healthy volunteers, patients with Cushing's syndrome, and patients with pseudo-Cushing states. J Clin Endocrinol Metab 1998; 83:1485.</a></li><li><a class="nounderline abstract_t">Biller BM, Federoff HJ, Koenig JI, Klibanski A. Abnormal cortisol secretion and responses to corticotropin-releasing hormone in women with hypothalamic amenorrhea. J Clin Endocrinol Metab 1990; 70:311.</a></li><li><a class="nounderline abstract_t">Luger A, Deuster PA, Kyle SB, et al. Acute hypothalamic-pituitary-adrenal responses to the stress of treadmill exercise. Physiologic adaptations to physical training. N Engl J Med 1987; 316:1309.</a></li><li><a class="nounderline abstract_t">Gold PW, Gwirtsman H, Avgerinos PC, et al. Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. N Engl J Med 1986; 314:1335.</a></li><li><a class="nounderline abstract_t">O'Brien JT, Ames D, Schweitzer I. HPA axis function in depression and dementia: A review. Int J Geriatr Psychiatry 1993; 8:887.</a></li><li><a class="nounderline abstract_t">Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA 1993; 269:2232.</a></li><li><a class="nounderline abstract_t">Galm BP, Qiao N, Klibanski A, et al. Accuracy of Laboratory Tests for the Diagnosis of Cushing Syndrome. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Rubinstein G, Osswald A, Hoster E, et al. Time to Diagnosis in Cushing's Syndrome: A Meta-Analysis Based on 5367 Patients. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Baid SK, Rubino D, Sinaii N, et al. Specificity of screening tests for Cushing's syndrome in an overweight and obese population. J Clin Endocrinol Metab 2009; 94:3857.</a></li><li><a class="nounderline abstract_t">Crapo L. Cushing's syndrome: a review of diagnostic tests. Metabolism 1979; 28:955.</a></li><li><a class="nounderline abstract_t">Mengden T, Hubmann P, Müller J, et al. Urinary free cortisol versus 17-hydroxycorticosteroids: a comparative study of their diagnostic value in Cushing's syndrome. Clin Investig 1992; 70:545.</a></li><li><a class="nounderline abstract_t">Hellman L, Weitzman ED, Roffwarg H, et al. Cortisol is secreted episodically in Cushing's syndrome. J Clin Endocrinol Metab 1970; 30:686.</a></li><li><a class="nounderline abstract_t">Sederberg-Olsen P, Binder C, Kehlet H, et al. Episodic variation in plasma corticosteroids in subjects with Cushing's syndrome of differing etiology. J Clin Endocrinol Metab 1973; 36:906.</a></li><li><a class="nounderline abstract_t">Van Cauter E, Refetoff S. Evidence for two subtypes of Cushing's disease based on the analysis of episodic cortisol secretion. N Engl J Med 1985; 312:1343.</a></li><li><a class="nounderline abstract_t">Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 2008; 93:1553.</a></li><li><a class="nounderline abstract_t">Kidambi S, Raff H, Findling JW. Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome. Eur J Endocrinol 2007; 157:725.</a></li><li><a class="nounderline abstract_t">Elias PC, Martinez EZ, Barone BF, et al. Late-night salivary cortisol has a better performance than urinary free cortisol in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2014; 99:2045.</a></li><li><a class="nounderline abstract_t">Raff H, Auchus RJ, Findling JW, Nieman LK. Urine free cortisol in the diagnosis of Cushing's syndrome: is it worth doing and, if so, how? J Clin Endocrinol Metab 2015; 100:395.</a></li><li><a class="nounderline abstract_t">Carroll BJ, Curtis GC, Davies BM, et al. Urinary free cortisol excretion in depression. Psychol Med 1976; 6:43.</a></li><li><a class="nounderline abstract_t">Mericq MV, Cutler GB Jr. High fluid intake increases urine free cortisol excretion in normal subjects. J Clin Endocrinol Metab 1998; 83:682.</a></li><li><a class="nounderline abstract_t">Meinardi JR, Wolffenbuttel BH, Dullaart RP. Cyclic Cushing's syndrome: a clinical challenge. Eur J Endocrinol 2007; 157:245.</a></li><li><a class="nounderline abstract_t">Alwani RA, Schmit Jongbloed LW, de Jong FH, et al. Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests. Eur J Endocrinol 2014; 170:477.</a></li><li><a class="nounderline abstract_t">Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999; 84:440.</a></li><li><a class="nounderline abstract_t">Castro M, Elias PC, Quidute AR, et al. Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab 1999; 84:878.</a></li><li><a class="nounderline abstract_t">Laudat MH, Cerdas S, Fournier C, et al. Salivary cortisol measurement: a practical approach to assess pituitary-adrenal function. J Clin Endocrinol Metab 1988; 66:343.</a></li><li><a class="nounderline abstract_t">Bonnin R, Villabona C, Rivera A, et al. Is salivary cortisol a better index than free cortisol in serum or urine for diagnosis of Cushing syndrome? Clin Chem 1993; 39:1353.</a></li><li><a class="nounderline abstract_t">Raff H, Raff JL, Findling JW. Late-night salivary cortisol as a screening test for Cushing's syndrome. J Clin Endocrinol Metab 1998; 83:2681.</a></li><li><a class="nounderline abstract_t">Putignano P, Toja P, Dubini A, et al. Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing's syndrome. J Clin Endocrinol Metab 2003; 88:4153.</a></li><li><a class="nounderline abstract_t">Papanicolaou DA, Mullen N, Kyrou I, Nieman LK. Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2002; 87:4515.</a></li><li><a class="nounderline abstract_t">Yaneva M, Mosnier-Pudar H, Dugué MA, et al. Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab 2004; 89:3345.</a></li><li><a class="nounderline abstract_t">Viardot A, Huber P, Puder JJ, et al. Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test. J Clin Endocrinol Metab 2005; 90:5730.</a></li><li><a class="nounderline abstract_t">Raff H, Homar PJ, Burns EA. Comparison of two methods for measuring salivary cortisol. Clin Chem 2002; 48:207.</a></li><li><a class="nounderline abstract_t">Liu H, Bravata DM, Cabaccan J, et al. Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin Endocrinol (Oxf) 2005; 63:642.</a></li><li><a class="nounderline abstract_t">Papanicolaou DA, Yanovski JA, Cutler GB Jr, et al. A single midnight serum cortisol measurement distinguishes Cushing's syndrome from pseudo-Cushing states. J Clin Endocrinol Metab 1998; 83:1163.</a></li><li><a class="nounderline abstract_t">Newell-Price J, Trainer P, Perry L, et al. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1995; 43:545.</a></li><li><a class="nounderline abstract_t">Blethen SL, Chasalow FI. Overnight dexamethasone suppression test: normal responses and the diagnosis of Cushing's syndrome. Steroids 1989; 54:185.</a></li><li><a class="nounderline abstract_t">Findling JW, Raff H, Aron DC. The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab 2004; 89:1222.</a></li><li><a class="nounderline abstract_t">Meikle AW. Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone. Clin Endocrinol (Oxf) 1982; 16:401.</a></li><li><a class="nounderline abstract_t">Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions. II. Arch Intern Med 1992; 152:711.</a></li><li><a class="nounderline abstract_t">Manetti L, Rossi G, Grasso L, et al. Usefulness of salivary cortisol in the diagnosis of hypercortisolism: comparison with serum and urinary cortisol. Eur J Endocrinol 2013; 168:315.</a></li><li><a class="nounderline abstract_t">Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications. J Endocrinol Invest 2006; 29:471.</a></li><li><a class="nounderline abstract_t">Alexandraki KI, Kaltsas GA, Isidori AM, et al. The prevalence and characteristic features of cyclicity and variability in Cushing's disease. Eur J Endocrinol 2009; 160:1011.</a></li><li><a class="nounderline abstract_t">Petersenn S, Newell-Price J, Findling JW, et al. High variability in baseline urinary free cortisol values in patients with Cushing's disease. Clin Endocrinol (Oxf) 2014; 80:261.</a></li></ol></div><div id="topicVersionRevision">Topic 151 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18334580" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26004339" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Whom should we screen for Cushing Syndrome? The Endocrine Society Clinical Practice Guideline Recommendations 2008 Revisited</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15251475" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cushing'S syndrome attributable to topical use of lotrisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7784285" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Iatrogenic Cushing's syndrome due to nasal betamethasone: a problem not to be sniffed at!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3753129" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cushing's syndrome from the therapeutic use of intramuscular dexamethasone acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250225" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755851" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23873267" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Triamcinolone and ritonavir leading to drug-induced Cushing syndrome and adrenal suppression: description of a new case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18377596" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Complications of chronic use of skin lightening cosmetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17452765" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A woman with Cushing's syndrome after use of an Indonesian herb: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9472211" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cushing syndrome due to surreptitious glucocorticoid administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238157" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Raised cortisol excretion rate in urine and contamination by topical steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8855803" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Factitious Cushing syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8989250" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7559895" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Factitious hypercortisoluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671138" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Diagnosis and complications of Cushing's syndrome: a consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9793762" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13761950" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1528959" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Psychiatric phenomenology in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2994764" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Differences in plasma ACTH and cortisol between depressed patients and normal controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2994590" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pituitary-adrenal axis rhythm disturbances in psychiatric depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3010108" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2838538" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The oCRH stimulation test before and after clinical recovery from depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8771359" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : On the mechanism of alcohol-induced pseudo-Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21934176" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Alcohol-induced Cushing syndrome. Hypercortisolism caused by alcohol abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9589643" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Plasma levels of corticotropin-releasing hormone in the inferior petrosal sinuses of healthy volunteers, patients with Cushing's syndrome, and patients with pseudo-Cushing states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2153693" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Abnormal cortisol secretion and responses to corticotropin-releasing hormone in women with hypothalamic amenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3033504" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acute hypothalamic-pituitary-adrenal responses to the stress of treadmill exercise. Physiologic adaptations to physical training.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3010109" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : HPA axis function in depression and dementia: A review</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8386285" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32133504" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Accuracy of Laboratory Tests for the Diagnosis of Cushing Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31665382" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Time to Diagnosis in Cushing's Syndrome: A Meta-Analysis Based on 5367 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19602562" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Specificity of screening tests for Cushing's syndrome in an overweight and obese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/225638" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cushing's syndrome: a review of diagnostic tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1327327" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Urinary free cortisol versus 17-hydroxycorticosteroids: a comparative study of their diagnostic value in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4315484" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cortisol is secreted episodically in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4698248" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Episodic variation in plasma corticosteroids in subjects with Cushing's syndrome of differing etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3873008" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evidence for two subtypes of Cushing's disease based on the analysis of episodic cortisol secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18334594" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057379" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24628557" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Late-night salivary cortisol has a better performance than urinary free cortisol in the diagnosis of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25423573" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Urine free cortisol in the diagnosis of Cushing's syndrome: is it worth doing and, if so, how?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/935296" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Urinary free cortisol excretion in depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9467592" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : High fluid intake increases urine free cortisol excretion in normal subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17766705" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cyclic Cushing's syndrome: a clinical challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24394725" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022398" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084565" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2828410" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Salivary cortisol measurement: a practical approach to assess pituitary-adrenal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8504555" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Is salivary cortisol a better index than free cortisol in serum or urine for diagnosis of Cushing syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709931" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Late-night salivary cortisol as a screening test for Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970280" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12364428" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15240613" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014408" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11751565" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of two methods for measuring salivary cortisol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16343098" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9543134" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A single midnight serum cortisol measurement distinguishes Cushing's syndrome from pseudo-Cushing states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8548938" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2588297" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Overnight dexamethasone suppression test: normal responses and the diagnosis of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15001614" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7094363" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1558427" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Update on rifampin drug interactions. II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23211575" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Usefulness of salivary cortisol in the diagnosis of hypercortisolism: comparison with serum and urinary cortisol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16794373" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289537" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The prevalence and characteristic features of cyclicity and variability in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23746264" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : High variability in baseline urinary free cortisol values in patients with Cushing's disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
